Crescent Biopharma (CBIO) Change in Accured Expenses (2013 - 2026)
Crescent Biopharma (CBIO) reported Change in Accured Expenses of -$3.5 million for Q1 2026, down 296.48% year-over-year from $1.8 million in Q1 2025, and down 226.35% on a QoQ basis from -$1.1 million in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 296.48% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148000.0 (down 95.03% YoY) and the FY2025 annual result came in at $5.4 million, up 3333.7% from the prior year.
- Change in Accured Expenses slipped to -$3.5 million in Q1 2026 per CBIO's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.7 million in Q2 2025 and bottomed at -$3.5 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is -$148473.0 (2023), against an average of -$104974.4.
- Peak annual rise in Change in Accured Expenses reached 2630.88% in 2024, while the deepest fall reached 869.97% in 2024.
- Tracing CBIO's Change in Accured Expenses over 5 years: stood at $1.2 million in 2022, then tumbled by 107.27% to -$85820.0 in 2023, then jumped by 2630.88% to $2.2 million in 2024, then sank by 148.76% to -$1.1 million in 2025, then tumbled by 226.35% to -$3.5 million in 2026.
- Per Business Quant, the three latest CBIO Change in Accured Expenses figures stand at -$3.5 million (Q1 2026), -$1.1 million (Q4 2025), and $2.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | -3.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.46 Mn |
| Mar 31, 2026 | -3.46 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Sep 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Jun 30, 2025 | 2.66 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Dec 31, 2024 | 2.17 Mn |
| Jun 30, 2024 | -951,062.00 |
| Jun 30, 2024 | -951,062.00 |
| Mar 31, 2024 | -1.32 Mn |
| Mar 31, 2024 | -1.32 Mn |
| Dec 31, 2023 | -85,820.00 |
| Dec 31, 2023 | -85,820.00 |
| Sep 30, 2023 | -198,895.00 |
| Sep 30, 2023 | -198,895.00 |
| Jun 30, 2023 | -98,051.00 |
| Jun 30, 2023 | -98,051.00 |
| Mar 31, 2023 | -1.38 Mn |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Dec 31, 2022 | 1.18 Mn |
| Sep 30, 2022 | -799,030.00 |
| Sep 30, 2022 | -799,030.00 |
| Jun 30, 2022 | -2.87 Mn |
| Jun 30, 2022 | -2.87 Mn |
| Mar 31, 2022 | 761,658.00 |
| Mar 31, 2022 | 761,658.00 |
| Dec 31, 2021 | 881,616.00 |
| Dec 31, 2021 | 881,616.00 |
| Sep 30, 2021 | -700,112.00 |
| Sep 30, 2021 | -700,112.00 |
| Jun 30, 2021 | 382,035.00 |
| Jun 30, 2021 | 382,035.00 |
| Mar 31, 2021 | -1.55 Mn |
| Mar 31, 2021 | -1.55 Mn |
| Dec 31, 2020 | 1.84 Mn |
| Dec 31, 2020 | 1.84 Mn |
| Sep 30, 2020 | 380,106.00 |
| Sep 30, 2020 | 380,106.00 |
| Jun 30, 2020 | 828,681.00 |
| Jun 30, 2020 | 828,681.00 |
| Mar 31, 2020 | -2.06 Mn |
| Mar 31, 2020 | -2.06 Mn |
| Dec 31, 2019 | 465,924.00 |
| Dec 31, 2019 | 465,924.00 |
| Sep 30, 2019 | 1.40 Mn |
| Sep 30, 2019 | 1.40 Mn |
| Jun 30, 2019 | 1.14 Mn |
| Jun 30, 2019 | 1.14 Mn |
| Mar 31, 2019 | -300,817.00 |
| Mar 31, 2019 | -300,817.00 |
| Dec 31, 2018 | 318,612.00 |
| Dec 31, 2018 | 318,612.00 |
| Sep 30, 2018 | 1.97 Mn |
| Sep 30, 2018 | 1.97 Mn |
| Jun 30, 2018 | -850,711.00 |
| Jun 30, 2018 | -850,711.00 |
| Mar 31, 2018 | -887,737.00 |
| Mar 31, 2018 | -887,737.00 |
| Dec 31, 2017 | 599,547.00 |
| Dec 31, 2017 | 599,547.00 |
| Sep 30, 2017 | 156,922.00 |
| Sep 30, 2017 | 156,922.00 |
| Jun 30, 2017 | 716,730.00 |
| Jun 30, 2017 | 716,730.00 |
| Mar 31, 2017 | -748,402.00 |
| Mar 31, 2017 | -748,402.00 |
| Dec 31, 2016 | 618,079.00 |
| Dec 31, 2016 | 618,079.00 |
| Sep 30, 2016 | -456,363.00 |
| Sep 30, 2016 | -456,363.00 |
| Jun 30, 2016 | 555,698.00 |
| Jun 30, 2016 | 555,698.00 |
| Mar 31, 2016 | -3.22 Mn |
| Mar 31, 2016 | -3.22 Mn |
| Dec 31, 2015 | 965,537.00 |
| Dec 31, 2015 | 965,537.00 |
| Sep 30, 2015 | 565,912.00 |
| Sep 30, 2015 | 565,912.00 |
| Jun 30, 2015 | 2.80 Mn |
| Jun 30, 2015 | 2.80 Mn |
| Mar 31, 2015 | -2.64 Mn |
| Mar 31, 2015 | -2.64 Mn |
| Dec 31, 2014 | 1.47 Mn |
| Dec 31, 2014 | 1.47 Mn |
| Sep 30, 2014 | 1.00 Mn |
| Sep 30, 2014 | 1.00 Mn |
| Jun 30, 2014 | 2.28 Mn |
| Jun 30, 2014 | 2.28 Mn |
| Mar 31, 2014 | -292,758.00 |
| Mar 31, 2014 | -292,758.00 |
| Dec 31, 2013 | 40,585.00 |
| Dec 31, 2013 | 40,585.00 |
| Sep 30, 2013 | 90,229.00 |
| Sep 30, 2013 | 90,229.00 |
| Jun 30, 2013 | 437,958.00 |
| Jun 30, 2013 | 437,958.00 |
| Mar 31, 2013 | -381,638.00 |
| Mar 31, 2013 | -381,638.00 |